Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record.

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia after failure of interferon-α

Kantarjian, Hagop M., Cortes, Jorge E., O'Brien, Susan, Luthra, Rajyalakshmi, Giles, Francis, Verstovsek, Srdan, Faderl, Stefan, Thomas, Deborah, Garcia-Manero, Guillermo, Rios, Mary Beth, Shan, Jianqin, Jones, Dan, Talpaz, Moshe · 2004 · Blood

Abstract

We reviewed 261 patients with chronicphase chronic myelogenous leukemia (CML) after interferon-α (IFN-α) failure treated with imatinib mesylate 400 mg daily. With a median follow-up time of 45 months, the major cytogenetic response rate was 73% and the complete cytogenetic response rate 63%. The estimated 4-year survival rate was 86%. Multivariate analysis for survival identified hematologic resistance to IFN-α (P = .01), splenomegaly (P = .03), and lack of any cytogenetic response after 3 months of therapy (P = .01) to have independent poor prognostic significance. Patients could be divided into good(no adverse factors), intermediate(1 adverse factor), and poor-risk groups (2 or 3 adverse factors; 12% of patients) with estimated 4-year survival rates of 96%, 86%, and 49%, respectively (P < .000 01). The 4-year cumulative major molecular response (quantitative reverse transcriptase–polymerase chain reaction [Q-PCR] = BCR-ABL/ABL less than 0.05%) rate was 43% and complete molecular response rate (BCR-ABL undetectable) 26%. Compared with a historical group of 251 similar patients treated with nonimatinib therapies, imatinib mesylate was associated with a better 4-year survival rate (86% versus 43%; P < .0001); the survival advantage was confirmed by multivariate analysis (hazard ratio, 0.19; P < .0001).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2004-02-0711

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Metadata

Authors
Kantarjian, H. M., Cortes, J. E., O'Brien, S., Luthra, R., Giles, F., Verstovsek, S., Faderl, S., Thomas, D., Garcia-Manero, G., Rios, M. B., Shan, J., Jones, D., & Talpaz, M.
Venue
Blood
Published
2004-10-01
Volume
104
Issue
7
Pages
1979-1988
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2157743993
Cited by
173
References
0
FWCI
14.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia after failure of interferon-α. https://app.cochat.ai/papers/10.1182/blood-2004-02-0711
The paper
Kantarjian, H. M., Cortes, J. E., O'Brien, S., Luthra, R., Giles, F., Verstovsek, S., Faderl, S., Thomas, D., Garcia-Manero, G., Rios, M. B., Shan, J., Jones, D., & Talpaz, M. (2004). Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood. https://doi.org/10.1182/blood-2004-02-0711

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.